Aptevo Therapeutics Reports Second Quarter Financial Results with Business HighlightsAccesswire • 08/12/21
Aptevo Therapeutics' Chief Scientific Officer, Jane Gross, PhD, to Present at Upcoming Cambridge Health Institute PEGS Virtual ConferenceAccesswire • 07/16/21
Aptevo Therapeutics Inc. (APVO) Moves 8.7% Higher: Will This Strength Last?Zacks Investment Research • 06/15/21
Aptevo Therapeutics Announces Expansion Phase of Lead Anti-Leukemia Drug APVO436 in Adult Patients with Acute Myeloid LeukemiaAccesswire • 05/27/21
Aptevo Stock Gains on Encouraging Single-Agent Activity for APVO436 In Leukemia PatientsBenzinga • 05/26/21
Aptevo Therapeutics Reports Positive Phase 1 Clinical Data for Its Lead Leukemia Drug Candidate APVO436 in Adults With Relapsed Acute Myeloid LeukemiaAccesswire • 05/26/21
Aptevo Therapeutics to Present at the American Association for Cancer Research Virtual Annual MeetingAccesswire • 04/09/21
Aptevo Therapeutics and Alligator Bioscience advancing the bispecific 4-1BBx5T4 antibody ALG.APV-527 into Phase I clinical developmentPRNewsWire • 11/16/20
All You Need to Know About Aptevo Therapeutics Inc. (APVO) Rating Upgrade to BuyZacks Investment Research • 06/30/20
Has Aptevo Therapeutics (APVO) Outpaced Other Medical Stocks This Year?Zacks Investment Research • 06/30/20
Aptevo Therapeutics and Alligator Bioscience Present new Preclinical Data for ALG.APV-527 at the PEGS Virtual Interactive Global SummitPRNewsWire • 06/10/20
Aptevo Therapeutics Receives Orphan Drug Designation for APVO436 for the Treatment of Acute Myelogenous LeukemiaGlobeNewsWire • 12/06/19